Can ISRG Stock Defend Its $131B Valuation?
This is a market-broadening year for Intuitive Surgical. The company is expanding beyond its core da Vinci systems to serve a wider continuum of hospitals and surgery centers.
Yet, procedure growth in the core U.S. market has moderated from recent trends. In response, management is innovating its operations for value-sensitive markets while continuing to repurchase its own stock.
That’s the story the market is currently paying 41.8x trailing earnings for. Is the growth implied by today’s price reasonable? Let’s unpack below.
Before we get into the math behind that valuation, ISRG’s current numbers are worth keeping in mind as a reference point:
- The Hospital Bet That Reframes The Intuitive Surgical Stock Story
- Intuitive Surgical Stock Has Fallen While Its Operating Margin Keeps Widening
- S&P 500 Movers | Winners: NDSN, COIN, DE | Losers: MRNA, WMT, ISRG
- Can ISRG Stock Survive A Drop To $280?
- The Paid-To-Hold Play On ISRG Stock: A 12% Annualized Income
- Two Years Of Growth Barely Change What You Pay For Intuitive Surgical
| ISRG | |
|---|---|
| Sector | Health Care |
| Industry | Health Care Equipment |
| P/E Ratio | 41.8 |
| P/E Ratio 3Y Avg | 65.7 |
| LTM Revenue Growth | 21% |
| 3Y Avg Revenue Growth | 18.4% |
| LTM Net Margin | 28% |
| 3Y Peak Net Margin | 29% |
| 3Y Avg Net Margin | 27% |
LTM refers to last twelve months.
What The Price Is Asking For
To defend ISRG’s $131.2B market cap over the next 4 years, three things have to play out. The multiple settles from today’s 41.8x toward 25.2x—a blended target anchored on the 22.0x multiple mature medical-device peers typically command, combined with the company’s own historical average capped at 30x. Margins land near 28%, anchored on the company’s own track record, which already runs at or above what mature peers earn. And revenue compounds from $11.0B today to $18.6B at maturity, supporting $5.2B of annual net income. That last line works out to a required revenue CAGR of 13.9%, below the 21% the business is currently running.
Is This Realistic?
The new da Vinci 5 system is driving a strong capital upgrade cycle. Placements in ambulatory surgery centers are also accelerating, while a new flexible endoscope for the GI tract has been submitted for regulatory clearance.
The primary risk is the source of the U.S. procedure slowdown. Management cites temporary patient coverage dynamics, but analysts question if it signals market maturation, noting other medical technology firms are not seeing a similar effect.
The multiple is demanding less than the business is currently delivering. The risks above are what would push performance below the line the multiple already assumes.
The company is building new growth avenues just as the maturity of its core U.S. market becomes a central question.
For a different read on ISRG, see our recent piece The Hospital Bet That Reframes The Intuitive Surgical Stock Story.
Should You Invest In Intuitive Surgical?
Even when current multiples leave room for execution, a single-stock thesis remains vulnerable to unexpected operational shocks and broader market downturns. Relying entirely on one name ignores the diversification benefit needed to navigate sector-wide volatility. The solution is a rule-based portfolio approach.
If it is exposure to healthcare as a whole you want rather than this one name, a healthcare ETF like XLV covers that single sector. Going broader than any one sector, to a quality-first mix across the whole market, is where the portfolio below comes in.
The Trefis High Quality (HQ) Portfolio combines analytical rigor with a forward-looking view across 30 stocks, with a consistent selection framework and sizing/rebalancing discipline designed to deliver upside without the single-name risk you just read through here.
By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.